KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: Comparison of methods and impact of histology

Journal of Molecular Diagnostics

Volumn 12, Issue 1, 2010, Pages 35-42

  Weichert, Wilko ^a   Schewe, Christiane ^a   Lehmann, Annika ^a   Sers, Christine ^a   Denkert, Carsten ^a   Budczies, Jan ^a   Stenzinger, Albrecht ^a   Joos, Hans ^a,b   Landt, Olfert ^c   Heiser, Volker ^d   Röcken, Christoph ^a   Dietel, Manfred ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Invitek Gesellschaft für Biotechnik und Biodesign MBH   (Germany)

^c TIB MOLBIOL Syntheselabor GmbH   (Germany)

^d Chipron GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PARAFFIN;

ANALYTIC METHOD; ARTICLE; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; DIAGNOSTIC ACCURACY; DNA DETERMINATION; DNA EXTRACTION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MELTING CURVE ANALYSIS; MICROARRAY ANALYSIS; ONCOGENE K RAS; PROSPECTIVE STUDY; PYROSEQUENCING; REPRODUCIBILITY; RETROSPECTIVE STUDY;

EID: 77349127129     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2010.090079     Document Type: Article

References (32)

1. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW: Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008, 44:1345-1389
2. Wolpin BM, Mayer RJ: Systemic treatment of colorectal cancer. Gastroenterology 2008, 134:1296-1310
3. Peeters M, Balfour J, Arnold D: Panitumumab-a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. Aliment Pharmacol Ther 2008, 28:269-281
4. Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI: Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol 2005, 23:5613-5619
5. Santoro A, Comandone A, Rimassa L, Granetti C, Lorusso V, Oliva C, Ronzoni M, Siena S, Zuradelli M, Mari E, Pressiani T, Carnaghi C: A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. Ann Oncol 2008, 19:1888-1893
6. Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Earle CC, Vincitore M, Michelini A, Sheehan S, Fuchs CS: Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastatic colorectal cancer. J Clin Oncol 2006, 24:1892-1897
7. Spano JP, Milano G, Vignot S, Khayat D: Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. Crit Rev Oncol Hematol 2008, 66:21-30
8. Hamilton SR: Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod Pathol 2008, 21:S23-S30
9. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201-1208
10. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345
11. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005, 6:279-286
12. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, Sobrero A, Barone C, Cascinu S, Colucci G, Cortesi E, Nichelatti M, Gambacorta M, Siena S: Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007, 25:3238-3245
13. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE: Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004, 351:2883
14. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634
15. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26:374-379
16. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-3995
17. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008, 19:508-515
18. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765
19. Raponi M, Winkler H, Dracopoli NC: KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol 2008, 8:413-418
20. Schewe C, Goldmann T, Grosser M, Zink A, Schlüns K, Pahl S, Ulrichs T, Kaufmann SH, Nerlich A, Baretton GB, Dietel M, Vollmer E, Petersen I: Inter-laboratory validation of PCR-based detection of Mycobacterium tuberculosis in formalin-fixed, paraffin-embedded tissues. Virchows Arch 2005, 447:573-585
21. Beranek M, Bure J, Sacha M, Sakra L, Rajman M, Jandik P, Rudolf E, Landt O: Detection of point mutations in kirsten ras 2 gene using locked nucleic acids clamped PCR. Chem Listy 2007, 101:738-741
22. Dietel M, Tannapfel A, Baretton G, Kreipe H, Kloor M, Gabbert H, Kirchner T: Molecular pathologic KRAS mutation analysis: a prerequisite of effective antibody treatment for metastasized colorectal cancer. Chirurg 2008, 79:576-579
23. Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, Valanzano R, Nobili S, Mini E, Pazzagli M, Orlando C: High-resolution melting analysis for rapid detection of KRAS. BRAF, and PIK3CA gene mutations in colorectal cancer Am J Clin Pathol 2008, 130:247-253
24. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS: Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 2005, 7:413-421
25. Clayton SJ, Scott FM, Walker J, Callaghan K, Haque K, Liloglou T, Xinarianos G, Shawcross S, Ceuppens P, Field JK, Fox JC: K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification. Clin Chem 2000, 46:1929-1938
26. Lilleberg SL, Durocher J, Sanders C, Walters K, Culver K: High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC.TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform Ann NY Acad Sci 2004, 1022:250-256
27. Rothschild CB, Brewer CS, Loggie B, Beard GA, Triscott MX: Detection of colorectal cancer K-ras mutations using a simplified oligonucleotide ligation assay. J Immunol Methods 1997, 206:11-19
28. Emanuel JR, Damico C, Ahn S, Bautista D, Costa J: Highly sensitive nonradioactive single-strand conformational polymorphism: detection of Ki-ras mutations. Diagn Mol Pathol 1996, 5:260-264
29. Keohavong P, Zhu D, Whiteside TL, Swalsky P, Bakker A, Elder EM, Siegfried JM, Srivastava S, Finkelstein SD: Detection of infrequent and multiple K-ras mutations in human tumors and tumor-adjacent tissues. Anal Biochem 1997, 247:394-403
30. Ward R, Hawkins N, O'Grady R, Sheehan C, O'Connor T, Impey H, Roberts N, Fuery C, Todd A: Restriction endonuclease-mediated selective polymerase chain reaction: a novel assay for the detection of K-ras mutations in clinical samples. Am J Pathol 1998, 153:373-379
31. Tannapfel A: Molecular pathology analysis of the KRAS mutation status in patients with metastasized colorectal carcinoma: an initial approach using predictive pathology. Pathologe 2008, 29:93-96
32. van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P, Fléjou JF, Hansen TP, de Hertogh G, Jares P, Langner C, Hoefler G, Ligtenberg M, Tiniakos D, Tejpar S, Bevilacqua G, Ensari A: KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for a European quality assurance program. Virchows Arch 2008, 453:417-431